129 related articles for article (PubMed ID: 18209648)
1. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
2. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
3. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
Tomsak RL; Zaret CR; Weidenthal D
Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
[No Abstract] [Full Text] [Related]
4. Dermatological side effects of brimonidine: a report of three cases.
Sodhi PK; Verma L; Ratan J
J Dermatol; 2003 Sep; 30(9):697-700. PubMed ID: 14578562
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced ectropion: what is best practice?
Hegde V; Robinson R; Dean F; Mulvihill HA; Ahluwalia H
Ophthalmology; 2007 Feb; 114(2):362-6. PubMed ID: 17270684
[TBL] [Abstract][Full Text] [Related]
6. Apparent central nervous system depression in infants after the use of topical brimonidine.
Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
[TBL] [Abstract][Full Text] [Related]
7. Anterior uveitis as a side effect of topical brimonidine.
Byles DB; Frith P; Salmon JF
Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
[TBL] [Abstract][Full Text] [Related]
8. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
10. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
12. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
13. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma.
Walters G; Taylor RH
Eye (Lond); 1999 Dec; 13 ( Pt 6)():797-8. PubMed ID: 10707152
[No Abstract] [Full Text] [Related]
14. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Bowman RJ; Cope J; Nischal KK
Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
[TBL] [Abstract][Full Text] [Related]
15. Reversible cicatricial ectropion associated with EGFR inhibitors.
Scofield-Kaplan S; Todaro J; Winn BJ
Orbit; 2018 Oct; 37(5):364-367. PubMed ID: 29336655
[TBL] [Abstract][Full Text] [Related]
16. A paradoxical ocular effect of brimonidine.
Mushtaq B; Sardar J; Matthews TD
Am J Ophthalmol; 2003 Jan; 135(1):102-3. PubMed ID: 12504711
[TBL] [Abstract][Full Text] [Related]
17. The teardrop sign: a rare dermatological reaction to brimonidine.
Scruggs JT; Whiteside-Michel J; Brodsky MC
Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
[No Abstract] [Full Text] [Related]
18. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
19. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Crichton AC
Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
[No Abstract] [Full Text] [Related]
20. Brimonidine and pupillary diameter.
Mastropasqua L; Carpineto P; Ciancaglini M
Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
[No Abstract] [Full Text] [Related]
[Next] [New Search]